CCL2 disrupts the adherens junction: Implications for neuroinflammation

Laboratory Investigation

Volumn 92, Issue 8, 2012, Pages 1213-1233

  Roberts, Toni K ^a   Eugenin, Eliseo A ^a,b,c   Lopez, Lillie ^a   Romero, Ignacio A ^d   Weksler, Babette B ^e   Couraud, Pierre Olivier ^f   Berman, Joan W ^a,g  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b PUBLIC HEALTH RESEARCH INSTITUTE   (United States)

^c RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^d OPEN UNIVERSITY   (United Kingdom)

^e WEILL CORNELL MEDICAL COLLEGE   (United States)

^f INSTITUT COCHIN   (France)

^g Department of Microbiology and Immunology ^*  (United States)

Author keywords

catenin; CD31; endothelial cells; MCP 1; neuroinflammation; PECAM 1; VE cadherin

Indexed keywords

BETA CATENIN; CD31 ANTIGEN; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEIN TYROSINE PHOSPHATASE SHP 2;

ADHERENT CELL; ARTICLE; BLOOD BRAIN BARRIER; CELL JUNCTION; CELL MEMBRANE; CONTROLLED STUDY; CYTOKINE RESPONSE; ENDOTHELIUM; HUMAN; HUMAN CELL; LEUKOCYTE; MICROVASCULAR ENDOTHELIAL CELL; NERVOUS SYSTEM INFLAMMATION; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; PROTEIN TRANSPORT;

ADHERENS JUNCTIONS; ANTIGENS, CD; ANTIGENS, CD31; BETA CATENIN; BRAIN; CADHERINS; CELL LINE; CELL MEMBRANE PERMEABILITY; CHEMOKINE CCL2; ENCEPHALITIS; ENDOTHELIAL CELLS; FOCAL ADHESION KINASE 1; HUMANS; MICROVESSELS; PHOSPHORYLATION; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 11; RECOMBINANT PROTEINS;

EID: 84864436756     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2012.80     Document Type: Article

References (109)

1. Graesser D, Solowiej A, Bruckner M, et al. Altered vascular permeability and early onset of experimental autoimmune encephalomyelitis in PECAM-1-deficient mice. J Clin Invest 2002;109: 383-392.
2. Navratil E, Couvelard A, Rey A, et al. Expression of cell adhesion molecules by microvascular endothelial cells in the cortical and subcortical regions of the normal human brain: an immunohistochemical analysis. Neuropathol Appl Neurobiol 1997;23: 68-80.
3. Petty MA, Lo EH. Junctional complexes of the blood-brain barrier: permeability changes in neuroinflammation. Prog Neurobiol 2002;68: 311-323.
4. Williams AJ, Wei HH, Dave JR, et al. Acute and delayed neuroinflammatory response following experimental penetrating ballistic brain injury in the rat. J Neuroinflamm 2007;4:17.
5. Alvarez JI, Teale JM. Evidence for differential changes of junctional complex proteins in murine neurocysticercosis dependent upon CNS vasculature. Brain Res 2007;1169:98-111.
6. Haorah J, Heilman D, Knipe B, et al. Ethanol-induced activation of myosin light chain kinase leads to dysfunction of tight junctions and blood-brain barrier compromise. Alcohol Clin Exp Res 2005;29: 999-1009.
7. Nottet HS. Interactions between macrophages and brain microvascular endothelial cells: role in pathogenesis of HIV-1 infection and blood-brain barrier function. J Neurovirol 1999;5: 659-669.
8. Ifergan I, Wosik K, Cayrol R, et al. Statins reduce human blood-brain barrier permeability and restrict leukocyte migration: relevance to multiple sclerosis. Ann Neurol 2006;60:45-55.
9. Weiss N, Miller F, Cazaubon S, et al. The blood-brain barrier in brain homeostasis and neurological diseases. Biochim Biophys Acta 2009;1788:842-857.
10. Wang P, Dai J, Bai F, et al. Matrix metalloproteinase 9 facilitates West Nile virus entry into the brain. J Virol 2008;82:8978-8985.
11. Zheng Y, Morris A, Sunkara M, et al. Epigallocatechin-gallate stimulates NF-E2-related factor and heme oxygenase-1 via caveolin-1 displacement. J Nutr Biochem 2012;23:163-168.
12. Caveda L, Martin-Padura I, Navarro P, et al. Inhibition of cultured cell growth by vascular endothelial cadherin (cadherin-5/VE-cadherin). J Clin Invest 1996;98:886-893.
13. Corada M, Mariotti M, Thurston G, et al. Vascular endothelial-cadherin is an important determinant of microvascular integrity in vivo. Proc Natl Acad Sci USA 1999;96:9815-9820.
14. Bibert S, Jaquinod M, Concord E, et al. Synergy between extracellular modules of vascular endothelial cadherin promotes homotypic hexameric interactions. J Biol Chem 2002;277:12790-12801.
15. Lampugnani MG, Corada M, Caveda L, et al. The molecular organization of endothelial cell to cell junctions: differential association of plakoglobin, beta-catenin, and alpha-catenin with vascular endothelial cadherin (VE-cadherin). J Cell Biol 1995;129: 203-217.
16. Knudsen KA, Soler AP, Johnson KR, et al. Interaction of alpha-actinin with the cadherin/catenin cell-cell adhesion complex via alphacatenin. J Cell Biol 1995;130:67-77.
17. Esser S, Lampugnani MG, Corada M, et al. Vascular endothelial growth factor induces VE-cadherin tyrosine phosphorylation in endothelial cells. J Cell Sci 1998;111(Part 13):1853-1865.
18. Andriopoulou P, Navarro P, Zanetti A, et al. Histamine induces tyrosine phosphorylation of endothelial cell-to-cell adherens junctions. Arterioscler Thromb Vasc Biol 1999;19:2286-2297.
19. van Wetering S, van Buul JD, Quik S, et al. Reactive oxygen species mediate Rac-induced loss of cell-cell adhesion in primary human endothelial cells. J Cell Sci 2002;115(Part 9):1837-1846.
20. Liao F, Huynh HK, Eiroa A, et al. Migration of monocytes across endothelium and passage through extracellular matrix involve separate molecular domains of PECAM-1. J Exp Med 1995;182: 1337-1343.
21. Ji G, O'Brien CD, Feldman M, et al. PECAM-1 (CD31) regulates a hydrogen peroxide-activated nonselective cation channel in endothelial cells. J Cell Biol 2002;157:173-184.
22. Park M, Hennig B, Toborek M. Methamphetamine alters occludin expression via NADPH oxidase-induced oxidative insult and intact caveolae. J Cell Mol Med 2012;16:362-375.
23. Williams DW, Eugenin EA, Calderon TM, et al. Monocyte maturation, HIV susceptibility, and transmigration across the blood brain barrier are critical in HIV neuropathogenesis. J Leukoc Biol 2012;91:401-415.
24. Mkrtchyan H, Scheler S, Klein I, et al. Molecular cytogenetic characterization of the human cerebral microvessel endothelial cell line hCMEC/D. Cytogenet Genome Res (Research Support, Non-US Gov't) 2009;126:313-317.
25. Vu K, Weksler B, Romero I, et al. Immortalized human brain endothelial cell line HCMEC/D3 as a model of the blood-brain barrier facilitates in vitro studies of central nervous system infection by Cryptococcus neoformans. Eukaryot Cell (Research Support, NIH, Extramural) 2009;8:1803-1807.
26. Weksler BB, Subileau EA, Perriere N, et al. Blood-brain barrier-specific properties of a human adult brain endothelial cell line. FASEB J 2005;19:1872-1874.
27. Cucullo L, Couraud PO, Weksler B, et al. Immortalized human brain endothelial cells and flow-based vascular modeling: a marriage of convenience for rational neurovascular studies. J Cereb Blood Flow Metab (Research Support, NIH, Extramural Research Support, Non-US Gov't) 2008;28:312-328.
28. Eugenin EA, Berman JW. Chemokine-dependent mechanisms of leukocyte trafficking across a model of the blood-brain barrier. Methods 2003;29:351-361.
29. Hurwitz AA, Berman JW, Lyman WD. The role of the blood-brain barrier in HIV infection of the central nervous system. Adv Neuroimmunol 1994;4:249-256.
30. Hurwitz AA, Berman JW, Rashbaum WK, et al. Human fetal astrocytes induce the expression of blood-brain barrier specific proteins by autologous endothelial cells. Brain Res 1993;625:238-243.
31. Weiss JM, Downie SA, Lyman WD, et al. Astrocyte-derived monocytechemoattractant protein-1 directs the transmigration of leukocytes across a model of the human blood-brain barrier. J Immunol 1998;161:6896-6903.
32. Eugenin EA, Berman JW. Gap junctions mediate human immunodeficiency virus-bystander killing in astrocytes. J Neurosci 2007;27:12844-12850.
33. Eugenin EA, Osiecki K, Lopez L, et al. CCL2/monocyte chemoattractant protein-1 mediates enhanced transmigration of human immunodeficiency virus (HIV)-infected leukocytes across the blood-brain barrier: a potential mechanism of HIV-CNS invasion and NeuroAIDS. J Neurosci 2006;26:1098-1106.
34. Kelder W, McArthur JC, Nance-Sproson T, et al. Beta-chemokines MCP-1 and RANTES are selectively increased in cerebrospinal fluid of patients with human immunodeficiency virus-associated dementia. Ann Neurol 1998;44:831-835.
35. Spanaus KS, Nadal D, Pfister HW, et al. C-X-C and C-C chemokines are expressed in the cerebrospinal fluid in bacterial meningitis and mediate chemotactic activity on peripheral blood-derived polymorphonuclear and mononuclear cells in vitro. J Immunol 1997;158:1956-1964.
36. Dogan RN, Elhofy A, Karpus WJ. Production of CCL2 by central nervous system cells regulates development of murine experimental autoimmune encephalomyelitis through the recruitment of TNF-and iNOS-expressing macrophages and myeloid dendritic cells. J Immunol 2008;180:7376-7384.
37. Galimberti D, Schoonenboom N, Scarpini E, et al. Chemokines in serum and cerebrospinal fluid of Alzheimer's disease patients. Ann Neurol 2003;53:547-548.
38. Iikuni N, Okamoto H, Yoshio T, et al. Raised monocyte chemotactic protein-1 (MCP-1)/CCL2 in cerebrospinal fluid of patients with neuropsychiatric lupus. Ann Rheum Dis 2006;65:253-256.
39. Stamatovic SM, Shakui P, Keep RF, et al. Monocyte chemoattractant protein-1 regulation of blood-brain barrier permeability. J Cereb Blood Flow Metab 2005;25:593-606.
40. Song L, Pachter JS. Monocyte chemoattractant protein-1 alters expression of tight junction-associated proteins in brain microvascular endothelial cells. Microvasc Res 2004;67:78-89.
41. Dimitrijevic OB, Stamatovic SM, Keep RF, et al. Effects of the chemokine CCL2 on blood-brain barrier permeability during ischemia-reperfusion injury. J Cereb Blood Flow Metab 2006;26:797-810.
42. Charo IF, Myers SJ, Herman A, et al. Molecular cloning and functional expression of two monocyte chemoattractant protein 1 receptors reveals alternative splicing of the carboxyl-terminal tails. Proc Natl Acad Sci USA 1994;91:2752-2756.
43. Gu L, Tseng SC, Rollins BJ. Monocyte chemoattractant protein-1. Chem Immunol 1999;72:7-29.
44. Dzenko KA, Andjelkovic AV, Kuziel WA, et al. The chemokine receptor CCR2 mediates the binding and internalization of monocyte chemoattractant protein-1 along brain microvessels. J Neurosci 2001; 21:9214-9223.
45. Dzenko KA, Song L, Ge S, et al. CCR2 expression by brain microvascular endothelial cells is critical for macrophage transendothelial migration in response to CCL2. Microvasc Res 2005;70:53-64.
46. Ge S, Song L, Serwanski DR, et al. Transcellular transport of CCL2 across brain microvascular endothelial cells. J Neurochem 2008;104: 1219-1232.
47. Andjelkovic AV, Pachter JS. Characterization of binding sites for chemokines MCP-1 and MIP-1alpha on human brain microvessels. J Neurochem 2000;75:1898-1906.
48. Roberts TK, Buckner CM, Berman JW. Leukocyte transmigration across the blood-brain barrier: perspectives on neuroAIDS. Front Biosci 2010;15:478-536.
49. Yamauchi LM, Aliberti JC, Baruffi MD, et al. The binding of CCL2 to the surface of Trypanosoma cruzi induces chemo-attraction and morphogenesis. Microbes Infect 2007;9:111-118.
50. Denney H, Clench MR, Woodroofe MN. Cleavage of chemokines CCL2 and CXCL10 by matrix metalloproteinases-2 and-9: implications for chemotaxis. Biochem Biophys Res Commun 2009;382: 341-347.
51. Stamatovic SM, Dimitrijevic OB, Keep RF, et al. Protein kinase Calpha-RhoA cross-talk in CCL2-induced alterations in brain endothelial permeability. J Biol Chem 2006;281:8379-8388.
52. Stamatovic SM, Keep RF, Wang MM, et al. Caveolae-mediated internalization of occludin and claudin-5 during CCL2-induced tight junction remodeling in brain endothelial cells. J Biol Chem 2009;284:19053-19066.
53. Mucha DR, Myers CL, Schaeffer Jr RC. Endothelial contraction and monolayer hyperpermeability are regulated by Src kinase. Am J Physiol Heart Circ Physiol 2003;284:H994-H1002.
54. Fincham VJ, Frame MC. The catalytic activity of Src is dispensable for translocation to focal adhesions but controls the turnover of these structures during cell motility. EMBO J 1998;17:81-92.
55. Wallez Y, Cand F, Cruzalegui F, et al. Src kinase phosphorylates vascular endothelial-cadherin in response to vascular endothelial growth factor: identification of tyrosine 685 as the unique target site. Oncogene 2007;26:1067-1077.
56. Groten T, Pierce AA, Huen AC, et al. 17 Beta-estradiol transiently disrupts adherens junctions in endothelial cells. FASEB J 2005;19:1368-1370.
57. Tinsley JH, Ustinova EE, Xu W, et al. Src-dependent, neutrophilmediated vascular hyperpermeability and beta-catenin modification. Am J Physiol Cell Physiol 2002;283:C1745-C1751.
58. Zhu H, Zhao J, Zhu B, et al. EMMPRIN regulates cytoskeleton reorganization and cell adhesion in prostate cancer. Prostate 2012;72:72-81.
59. Schlaepfer DD, Hunter T. Evidence for in vivo phosphorylation of the Grb2 SH2-domain binding site on focal adhesion kinase by Src-family protein-tyrosine kinases. Mol Cell Biol 1996;16:5623-5633.
60. Cheng YF, Kramer RH. Human microvascular endothelial cells express integrin-related complexes that mediate adhesion to the extracellular matrix. J Cell Physiol 1989;139:275-286.
61. Ilic D, Furuta Y, Kanazawa S, et al. Reduced cell motility and enhanced focal adhesion contact formation in cells from FAK-deficient mice. Nature 1995;377:539-544.
62. Calalb MB, Polte TR, Hanks SK. Tyrosine phosphorylation of focal adhesion kinase at sites in the catalytic domain regulates kinase activity: a role for Src family kinases. Mol Cell Biol 1995;15:954-963.
63. Helmke BP, Goldman RD, Davies PF. Rapid displacement of vimentin intermediate filaments in living endothelial cells exposed to flow. Circ Res 2000;86:745-752.
64. Angelini DJ, Hyun SW, Grigoryev DN, et al. TNF-alpha increases tyrosine phosphorylation of vascular endothelial cadherin and opens the paracellular pathway through fyn activation in human lung endothelia. Am J Physiol Lung Cell Mol Physiol 2006;291:L1232-L1245.
65. Lampugnani MG, Corada M, Andriopoulou P, et al. Cell confluence regulates tyrosine phosphorylation of adherens junction components in endothelial cells. J Cell Sci 1997;110(Part 17):2065-2077.
66. Potter MD, Barbero S, Cheresh DA. Tyrosine phosphorylation of VEcadherin prevents binding of p120-and beta-catenin and maintains the cellular mesenchymal state. J Biol Chem 2005;280:31906-31912.
67. Roura S, Miravet S, Piedra J, et al. Regulation of E-cadherin/catenin association by tyrosine phosphorylation. J Biol Chem 1999;274:36734-36740.
68. Bogatcheva NV, Garcia JG, Verin AD. Role of tyrosine kinase signaling in endothelial cell barrier regulation. Vasc Pharmacol 2002;39: 201-212.
69. Navaratna D, McGuire PG, Menicucci G, et al. Proteolytic degradation of VE-cadherin alters the blood-retinal barrier in diabetes. Diabetes 2007;56:2380-2387.
70. Ilan N, Mahooti S, Rimm DL, et al. PECAM-1 (CD31) functions as a reservoir for and a modulator of tyrosine-phosphorylated betacatenin. J Cell Sci 1999;112(Part 18):3005-3014.
71. Ilan N, Mohsenin A, Cheung L, et al. PECAM-1 shedding during apoptosis generates a membrane-anchored truncated molecule with unique signaling characteristics. FASEB J 2001;15:362-372.
72. Newman DK, Hamilton C, Newman PJ. Inhibition of antigen-receptor signaling by platelet endothelial cell adhesion molecule-1 (CD31) requires functional ITIMs, SHP-2, and p56(lck). Blood 2001;97: 2351-2357.
73. Cao MY, Huber M, Beauchemin N, et al. Regulation of mouse PECAM-1 tyrosine phosphorylation by the Src and Csk families of proteintyrosine kinases. J Biol Chem 1998;273:15765-15772.
74. Lu TT, Barreuther M, Davis S, et al. Platelet endothelial cell adhesion molecule-1 is phosphorylatable by c-Src, binds Src-Src homology 2 domain, and exhibits immunoreceptor tyrosine-based activation motif-like properties. J Biol Chem 1997;272:14442-14446.
75. Biswas P, Canosa S, Schoenfeld D, et al. PECAM-1 affects GSK-3betamediated beta-catenin phosphorylation and degradation. Am J Pathol 2006;169:314-324.
76. Jackson DE, Kupcho KR, Newman PJ. Characterization of phosphotyrosine binding motifs in the cytoplasmic domain of platelet/endothelial cell adhesion molecule-1 (PECAM-1) that are required for the cellular association and activation of the proteintyrosine phosphatase, SHP-2. J Biol Chem 1997;272:24868-24875.
77. Newman PJ. The role of PECAM-1 in vascular cell biology. Ann N Y Acad Sci 1994;714:165-174.
78. Muller WA, Ratti CM, McDonnell SL, et al. A human endothelial cellrestricted, externally disposed plasmalemmal protein enriched in intercellular junctions. J Exp Med 1989;170:399-414.
79. Sharief MK, Ciardi M, Thompson EJ. Blood-brain barrier damage in patients with bacterial meningitis: association with tumor necrosis factor-alpha but not interleukin-1 beta. J Infect Dis 1992;166:350-358.
80. Del Maschio A, De Luigi A, Martin-Padura I, et al. Leukocyte recruitment in the cerebrospinal fluid of mice with experimental meningitis is inhibited by an antibody to junctional adhesion molecule (JAM). J Exp Med 1999;190:1351-1356.
81. Navia BA, Cho ES, Petito CK, et al. The AIDS dementia complex: II. Neuropathology. Ann Neurol 1986;19:525-535.
82. Petito CK, Cash KS. Blood-brain barrier abnormalities in the acquired immunodeficiency syndrome: immunohistochemical localization of serum proteins in postmortem brain. Ann Neurol 1992;32:658-666.
83. Zilka N, Stozicka Z, Kovac A, et al. Human misfolded truncated tau protein promotes activation of microglia and leukocyte infiltration in the transgenic rat model of tauopathy. J Neuroimmunol 2009;209: 16-25.
84. Zipser BD, Johanson CE, Gonzalez L, et al. Microvascular injury and blood-brain barrier leakage in Alzheimer's disease. Neurobiol Aging 2007;28:977-986.
85. Gay D, Esiri M. Blood-brain barrier damage in acute multiple sclerosis plaques. An immunocytological study. Brain 1991;114(Part 1B):557-572.
86. Frohman EM, Racke MK, Raine CS. Multiple sclerosis-the plaque and its pathogenesis. N Engl J Med 2006;354:942-955.
87. Ellis SG, Verity MA. Central nervous system involvement in systemic lupus erythematosus: a review of neuropathologic findings in 57 cases, 1955-1977. Semin Arthritis Rheum 1979;8:212-221.
88. Winfield JB, Shaw M, Silverman LM, et al. Intrathecal IgG synthesis and blood-brain barrier impairment in patients with systemic lupus erythematosus and central nervous system dysfunction. Am J Med 1983;74:837-844.
89. Neumann-Haefelin T, Kastrup A, de Crespigny A, et al. Serial MRI after transient focal cerebral ischemia in rats: dynamics of tissue injury, blood-brain barrier damage, and edema formation. Stroke 2000;31:1965-1972; discussion 72-3.
90. Barone FC, Hillegass LM, Tzimas MN, et al. Time-related changes in myeloperoxidase activity and leukotriene B4 receptor binding reflect leukocyte influx in cerebral focal stroke. Mol Chem Neuropathol 1995;24:13-30.
91. McManus C, Berman JW, Brett FM, et al. MCP-1, MCP-2 and MCP-3 expression in multiple sclerosis lesions: an immunohistochemical and in situ hybridization study. J Neuroimmunol 1998;86:20-29.
92. Sprenger H, Rosler A, Tonn P, et al. Chemokines in the cerebrospinal fluid of patients with meningitis. Clin Immunol Immunopathol 1996;80:155-161.
93. Losy J, Zaremba J. Monocyte chemoattractant protein-1 is increased in the cerebrospinal fluid of patients with ischemic stroke. Stroke 2001;32:2695-2696.
94. Bell MD, Taub DD, Perry VH. Overriding the brain's intrinsic resistance to leukocyte recruitment with intraparenchymal injections of recombinant chemokines. Neuroscience 1996;74:283-292.
95. Stamatovic SM, Keep RF, Kunkel SL, et al. Potential role of MCP-1 in endothelial cell tight junction 'opening': signaling via Rho and Rho kinase. J Cell Sci 2003;116(Part 22):4615-4628.
96. Yap AS, Brieher WM, Gumbiner BM. Molecular and functional analysis of cadherin-based adherens junctions. Annu Rev Cell Dev Biol 1997;13:119-146.
97. Hicke L. Protein regulation by monoubiquitin. Nat Rev Mol Cell Biol 2001;2:195-201.
98. Hagen T, Di Daniel E, Culbert AA, et al. Expression and characterization of GSK-3 mutants and their effect on beta-catenin phosphorylation in intact cells. J Biol Chem 2002;277:23330-23335.
99. Liu C, Kato Y, Zhang Z, et al. Beta-Trcp couples beta-catenin phosphorylation-degradation and regulates Xenopus axis formation. Proc Natl Acad Sci USA 1999;96:6273-6278.
100. Pellegatta F, Chierchia SL, Zocchi MR. Functional association of platelet endothelial cell adhesion molecule-1 and phosphoinositide 3-kinase in human neutrophils. J Biol Chem 1998;273:27768-27771.
101. Hwang IK, Kim DW, Yoo KY, et al. Ischemia-induced changes of platelet endothelial cell adhesion molecule-1 in the hippocampal CA1 region in gerbils. Brain Res 2005;1048:251-257.
102. Muller WA, Weigl SA, Deng X, et al. PECAM-1 is required for transendothelial migration of leukocytes. J Exp Med 1993;178: 449-460.
103. Liao F, Ali J, Greene T, et al. Soluble domain 1 of platelet-endothelial cell adhesion molecule (PECAM) is sufficient to block transendothelial migration in vitro and in vivo. J Exp Med 1997;185:1349-1357.
104. Keuschnigg J, Henttinen T, Auvinen K, et al. The prototype endothelial marker PAL-E is a leukocyte trafficking molecule. Blood 2009;114:478-484.
105. Werdich XQ, Penn JS. Src, Fyn and Yes play differential roles in VEGFmediated endothelial cell events. Angiogenesis 2005;8:315-326.
106. Weis S, Cui J, Barnes L, et al. Endothelial barrier disruption by VEGFmediated Src activity potentiates tumor cell extravasation and metastasis. J Cell Biol 2004;167:223-229.
107. Porkka K, Koskenvesa P, Lundan T, et al. Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia. Blood 2008;112:1005-1012.
108. Zhong Y, Zhang B, Eum SY, et al. HIV-1 Tat triggers nuclear localization of ZO-1 via Rho signaling and cAMP response elementbinding protein activation. J Neurosci 2012;32:143-150.
109. Sipos E, Chen L, Andras IE, et al. Proinflammatory adhesion molecules facilitate polychlorinated biphenyl-mediated enhancement of brain metastasis formation. Toxicol Sci 2012;126:362-371.